20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
PaxMedica Inc (NASDAQ:PXMD) shares are trading higher by 175% to $8.39 Tuesday morning after the company announced research findings in the Annals of General Psychiatry regarding a study on low-dose suramin intravenous infusions as a potential treatment for Autism Spectrum Disorder.
The study involved 52 boys aged 4-15 with moderate to severe ASD and demonstrated promising results in improving core symptoms, particularly with the 10 mg/kg suramin infusion.
The study's main objective was to assess the effectiveness and safety of suramin intravenous infusions. The group receiving a 10 mg/kg suramin dose showed promising improvements in core symptoms.
Additionally, statistically significant enhancements were observed in the Clinical Global Impressions-Improvement (CGI-I) scale in this 10 mg/kg group when compared to the placebo group.
The company says this research represents a significant advancement in understanding ASD treatment options, with the company committed to improving the lives of those with ASD.
See Also: Uber Reports Q3 Results
According to data from Benzinga Pro, PaxMedica has a 52-week high of $69.22 and a 52-week low of $2.50.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!